Clinical Trial

A Study of PM8002 in Combination With Chemotherapy in Patients With NEN

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with FOLFIRI as second line treatment for neuroendocrine neoplasm (NEC and Ki-67≥55% G3 NET).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-05-25; most recent amendment 2026-07-08.
Status change: Recruiting → Active, Not Recruiting 2026-07-08
Trial Details
NCT Number NCT05879055
Lead Sponsor Biotheus Inc.
Conditions Neuroendocrine Neoplasm
Enrollment 31 participants
Start Date 2023-05-17
Primary Completion 2027-01-01 (estimated)
Study Completion 2028-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-09